Welcome to our dedicated page for Koru Med Sys SEC filings (Ticker: KRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for KORU Medical Systems, Inc. (NASDAQ: KRMD), a medical technology company focused on large-volume subcutaneous infusion solutions. These regulatory documents offer detailed information on the company’s operations, financial condition, risk factors, and material agreements related to its Freedom Syringe Infusion System and associated businesses.
Through its periodic reports, such as Form 10-K annual reports and Form 10-Q quarterly reports, KORU Medical discloses audited and interim financial statements, segment information for its core business and Pharma Services and Clinical Trials activities, and discussions of factors affecting demand for its subcutaneous infusion devices and services. These filings also describe the structure of the Freedom System, its regulatory status, and the company’s role in supporting large-volume subcutaneous drug delivery.
Form 8-K current reports document material events, including the public release of financial results, updated guidance, and key contracts. Recent 8-K filings have referenced press releases on preliminary and quarterly financial results and an Amended and Restated Manufacturing and Supply Agreement with Command Medical Products, Inc., which covers the manufacture and supply of subassemblies, needle sets, and tubing products for KORU Medical.
Investors can also review proxy statements for information on executive compensation, equity awards, and corporate governance, as well as Form 4 insider transaction reports that show purchases, sales, or grants of KORU Medical common stock by directors and officers under the KRMD ticker.
On Stock Titan, KORU Medical’s SEC filings are updated as new documents are posted to the SEC’s EDGAR system. AI-powered tools can summarize lengthy filings such as 10-Ks and 10-Qs, highlight key sections on revenue drivers, manufacturing and supply arrangements, and non-GAAP metrics like adjusted EBITDA, and help users quickly locate discussions of regulatory submissions, pharma collaborations, and other factors relevant to KRMD’s subcutaneous infusion business.
First Light Asset Management, LLC and Mathew P. Arens reported their beneficial ownership of KORU Medical Systems, Inc. common stock on an amended Schedule 13G. First Light Asset Management is deemed to beneficially own 3,721,508 shares, representing 8.03% of the outstanding common stock.
Mathew P. Arens, as managing member and majority owner of the Manager, is deemed to beneficially own 3,831,475 shares, or 8.27% of the class, including 88,167 shares he holds directly and 21,800 shares in a joint account. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of KORU Medical Systems.
Topline Capital Partners and affiliates have disclosed an 8.5% beneficial stake in KORU Medical Systems, Inc. As of February 13, 2026, the fund beneficially owns 3,941,014 shares of KORU’s common stock.
The shares are held by Topline Capital Partners, with Topline Capital Management, LLC and Collin McBirney potentially deemed beneficial owners due to their control roles. They expressly state the position is held in the ordinary course of business and not for the purpose of changing or influencing control of KORU Medical.
KORU Medical Systems, Inc. received an amended Schedule 13D from Horton Capital entities and Joseph M. Manko, Jr. updating their investment position. As of the close of business on February 13, 2026, Horton Capital Partners Fund, LP directly owns 5,062,498 shares of common stock, representing 10.93% of KORU Medical’s outstanding shares based on 46,322,655 shares reported as of November 12, 2025. Including shares held directly by Mr. Manko, his aggregate beneficial ownership is reported as 5,845,045 shares, or 12.62% of the company.
The amendment details multiple in-kind distributions of KORU Medical shares by Horton Capital funds to their limited partners and members, as well as periodic “Director Shares” issued to Horton Capital Partners Fund in consideration for Mr. Manko’s board service. The reporting persons state that the shares are held for investment purposes but may be increased or reduced over time and that they may engage with KORU Medical’s management, board, and other stockholders on issues such as capitalization, ownership structure, board composition, or operations.
KORU Medical Systems, Inc. insider entities associated with director and 10% owner Joseph M. Manko Jr. reported several transactions in common stock on February 13, 2026, all at a reported price of $0 per share under transaction code J.
After these transactions, Horton Capital Partners Fund, LP indirectly held 5,062,498 shares, Horton Capital Partners, LLC indirectly held 750,000 shares, and Manko directly held 782,547 shares. The filing emphasizes that it should not be construed as an admission of beneficial ownership of the reported securities.
KORU Medical Systems, Inc. amended and restated its By-laws effective February 5, 2026. The Board updated the By-laws to address Securities and Exchange Commission rules on universal proxy cards and to reflect a periodic review of governance provisions.
The revisions enhance procedural mechanics and disclosure requirements for stockholders who nominate directors or submit proposals at annual and special meetings. Changes include additional disclosures, representations and acknowledgments from nominating or proposing stockholders and their nominees, and revised advance notice deadlines for director nominations when the number of directors increases under certain circumstances.
BlackRock, Inc. has filed a Schedule 13G reporting a passive ownership stake in Koru Medical Systems Inc. As of 12/31/2025, BlackRock reports beneficial ownership of 2,345,369 shares of Koru Medical common stock, representing 5.1% of the outstanding class.
BlackRock indicates sole voting power over 2,308,684 shares and sole dispositive power over all 2,345,369 shares, with no shared voting or dispositive power. The filing states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Koru Medical, reflecting a non-activist, investment-focused position.
KORU Medical Systems reported that its Chief Technology Officer, Eric Schiller, received new equity awards on January 2, 2026. He was granted 76,426 shares of common stock at a price of $0, described as restricted stock issued as an employment inducement award that will vest 25% annually starting on January 2, 2027. He was also granted an option to buy 232,297 shares of common stock with an exercise price of $5.7 per share, with one-fourth of the option scheduled to vest on January 2, 2027 and on each of the first, second and third anniversaries of that date.
KORU Medical Systems, Inc. filed a Form 3 for Chief Technology Officer Eric Schiller reporting his initial beneficial ownership in the company. As of the event date of 12/29/2025, the filing shows he beneficially owns 0 shares of common stock, held directly. A Form 3 is an initial statement of ownership that insiders must file when they become subject to reporting rules.
KORU Medical Systems, Inc. reported that it has released a press release with certain preliminary financial results for the fiscal quarter and full year ended December 31, 2025. These figures are based on the company’s current estimates and may change after completion of its normal closing and review procedures. The details of the preliminary results are provided in the press release included as Exhibit 99.1. The company specifies that this information is being furnished rather than filed under securities laws, which affects how it is incorporated into other regulatory documents.
KORU Medical Systems, Inc.75,000 restricted stock units (RSUs)
One-fourth of the RSUs will vest on January 2, 202775,000 derivative securities$0 per unit